格隆汇1月5日丨巨子生物(02367.HK)公告，1月5日耗资1358.2万港元回购40万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 巨子生物控股有限公司 呈交日期： 2026年1月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02367 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | | | | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股 ...

Core Insights - The strategic partnership between Yuansong Group and Chongshan Biotechnology has led to the launch of the world's first collagen product derived from bovine tendons, named "Jiaoyuan Angel," which received Class III medical device registration approval from the National Medical Products Administration on December 10, 2025 [1][3] - The collagen market in China has reached a scale of 200 billion, with projections to grow to 500 billion by 2030, indicating significant growth potential in the industry [3] Product Advantages - "Jiaoyuan Angel" features a high concentration of medical collagen at 45 mg/ml, ensuring strong support [5] - The product is made from high-purity bovine tendon collagen, which guarantees the integrity of the raw material [5] - Advanced application technology allows for precise subcutaneous implantation, providing deeper support for the skin [5] - The development team overcame several technical challenges, establishing 45 mg/ml as the optimal concentration to balance collagen network formation and safety [5] - The product maintains biological activity and structural integrity through meticulous production processes [5] Market Trends - The introduction of "Jiaoyuan Angel" is expected to shift the focus of collagen applications from immediate filling effects to a trend of nutritional tightening in the industry [7] - Yuansong Group has established a strong presence in the medical aesthetics sector with several successful products, positioning itself as a market leader [7] - Analysts predict that "Jiaoyuan Angel" could capture significant market share quickly, potentially becoming a dark horse in the medical aesthetics market by 2026 [7]

Group 1 - The core viewpoint of the article highlights the positive performance of the healthcare sector, particularly in the fields of collagen and skincare products, with significant growth opportunities identified [1] - The Medical Industry ETF (159877.SZ) increased by 4.05%, and Lepu Medical surged by 19.99%, indicating strong market interest and investor confidence in the sector [1] - Jianghai Securities emphasizes the multi-dimensional investment logic in the healthcare industry, particularly in the collagen sector, where new entrants like Chuangjian Medical are gaining traction with their cross-linked collagen implants [1] Group 2 - The approval of cross-linked collagen products by Chuangjian Medical positions it as a strong competitor in the market, following the successes of Jinbo Biology and Juzhi Biology [1] - The "oil-based skincare" segment is projected to see sales exceeding 9.5 billion yuan from March 2024 to February 2025, reflecting a 36% growth, driven by advancements in domestic brands [1] - Continuous improvements in ingredients, technology, and formulations are enhancing industry standards, further propelling growth in the healthcare sector [1]

Investment Rating - The industry investment rating is "stronger than the market," indicating that the industry index is expected to outperform the market by more than 5% within the next six months [24]. Core Insights - The overall market performance is stable, with significant differentiation within the consumer sector. The upcoming New Year holiday is expected to boost certain segments, supported by favorable macro consumption policies that may lead to a recovery in consumer demand [3][4]. - The tourism sector shows potential for growth, with leading companies like Ctrip and Huazhu Hotels responding quickly to changing consumer demands. The retail tourism industry is stabilizing, with expectations for sales recovery [3][8]. - The beauty industry is experiencing steady growth, with a focus on companies that can quickly adapt to market dynamics and integrate products, brands, and channels [3]. - The film industry saw a strong performance during the New Year holiday, with box office revenues reaching 734 million yuan, led by the film "Zootopia 2" [14]. - In the food and beverage sector, the home dining market is expanding, with companies like Guoquan showing strong growth potential. The dairy supply-demand relationship is improving, and the restaurant supply chain is stabilizing [3][18]. - In the liquor segment, major companies are experiencing deeper profit adjustments, but leading brands are expected to maintain or increase market share due to superior management and branding [3][19]. Summary by Sections Social Services - The tourism sector is evolving, with a notable increase in travel demand during the New Year holiday, driven by a surge in ticket bookings and hotel reservations [8]. - Turkey has announced visa-free entry for Chinese passport holders, which is expected to enhance tourism flows [8]. Media - The film industry achieved a record box office during the New Year holiday, indicating strong consumer interest and spending in entertainment [14]. Food and Beverage - General - The home dining market is expanding, with companies like Guoquan leading the way. The dairy industry is seeing improved supply-demand dynamics, while the restaurant supply chain is stabilizing [3][18]. Food and Beverage - Alcohol - Major liquor companies are adjusting their profit margins, but leading brands are expected to capture more market share due to their strong brand presence and management capabilities [3][19].

枭雄要成就霸业，需要的不只是一招鲜，而是长期源源不断的竞争力。 陕西女首富范代娣和前山东女首富赵燕，如果不做医美，不关注护肤成分，你可能对这两个名字并不熟 悉。但在如今的中国商业版图上，这两位女性，分别掌控着两家市值几百亿的上市公司——巨子生物和 华熙生物。 表面上看，她们一个在西安，一个在山东；一个做蛋白，一个做多糖；一个出身严谨的大学实验室，一 个来自野蛮生长的地产江湖。她们本该井水不犯河水。 但现实是，这两家公司正在进行一场旷日持久的、甚至可以说是「你死我活」的商战。 但命运和机遇有时候就是不讲道理。 这一年，在北大EMBA的课堂上，她结识了山东省生物药物研究院的副院长郭学平。他跟赵燕说了一句 至今被奉为行业金句的话：「一个玻尿酸分子，能锁住1000个水分子。」 故事的起点，要回到2000年。 这是一个神奇的年份，两人的命运在这一年同时被改写。 当时的赵燕，还是一个在海南淘金成功、在北京开发楼盘的地产大鳄。后来更是在北京开发了中环世贸 中心，承建了奥运会场馆五棵松体育馆，也就是现在的五棵松华熙Live。 按理来说，她的头衔，应该是地产女王，而不是现在的「玻尿酸女王」。 01 她没有亲自去搞研发，而是用资 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The retail industry is undergoing an evolution in the "people, goods, and scene" framework, driven by emotional consumption, which presents new opportunities for growth [3][25] - High-end gold and fashion jewelry are gaining traction among consumers, with a focus on product differentiation and cultural significance [3][32] - The cosmetics industry is innovating through the IP of technical ingredients and cultural confidence, enhancing product appeal and market competitiveness [3][37] - Offline retail is shifting from selling "goods" to offering "services and experiences," with companies like Yonghui Supermarket leading the transformation [3][41] Summary by Sections Retail Market Overview - In 2025, the retail sector index closed at 2422.59 points, with an annual increase of 8.21%, underperforming the Shanghai Composite Index, which rose by 18.41% [5][14] - The retail industry ranked 23rd among 31 sectors in terms of performance [15] Industry Dynamics - The emotional value is driving consumer intentions, with a focus on "research-based consumption," "self-satisfaction," and "long-termism" as key decision-making trends [25][28] - High-end gold is becoming a preferred asset for wealth preservation, while fashion gold is appealing to younger consumers through innovative designs and social media engagement [32] - The cosmetics sector is witnessing a shift towards self-developed core ingredients and cultural narratives, enhancing brand value [37] Investment Recommendations - Focus on high-quality companies in the emotional consumption theme, particularly in the gold jewelry sector, with recommendations for brands like Chao Hong Ji and Lao Pu Gold [6][50] - Emphasize offline retail companies adapting to market changes, such as Yonghui Supermarket and Ai Ying Shi [6][48] - Highlight cosmetics brands that innovate in emotional value and safety, including Mao Ge Ping and Po Lai Ya [6][48] - Consider differentiated medical beauty product manufacturers and leading medical beauty institutions, recommending companies like Ai Mei Ke and Ke Di-B [6][48]

Core Viewpoint - The Chinese cosmetics industry is projected to reach a market size of 1.1 trillion yuan, with domestic brands surpassing international brands in market share and consumer preference [1][2]. Group 1: High-Quality Development and New Productive Forces - The domestic cosmetics market retail sales are expected to reach 470 billion yuan by 2025, indicating a significant growth trajectory for the industry [2]. - New productive forces are essential for the high-quality development of the cosmetics industry, transitioning from traditional manufacturing to intelligent and lean production [4]. - New productive forces enhance production efficiency and product consistency through automation and intelligent equipment, addressing quality control challenges [4]. Group 2: Intelligent Manufacturing Practices of Domestic Brands - The past decade has seen a shift in the cosmetics manufacturing industry from experience-driven to data-driven processes, evolving through three stages: semi-automated, automated, and now data-driven intelligent stages [6]. - Leading brands like Han Shu and Pechoin have made significant investments in intelligent manufacturing, achieving production capacity increases and improved quality control [8][10]. - Domestic brands have made historical advancements in intelligent manufacturing, with automation rates rising from approximately 40% to levels comparable to international brands [10]. Group 3: R&D Innovation and Cost Management - R&D expenditure rates vary across different categories, with skincare products averaging 1.5%-5% and medical beauty products at 2%-5%, reflecting a focus on compliance and clinical data [21][23]. - Domestic brands like Han Shu and Pechoin have R&D personnel ratios comparable to international leaders, indicating strong R&D capabilities [24]. - The production cost rates for various product categories range from 15% to 30%, with domestic brands leveraging self-researched technologies and integrated supply chains to maintain competitive pricing [27][28]. Group 4: International Competitiveness of Domestic Brands - Domestic brands have achieved significant breakthroughs in the cosmetics sector, enhancing core competitiveness through new productive forces [31]. - Intelligent manufacturing has enabled micro-level quality control, establishing trust in product quality [33]. - The integration of AI and 5G technologies in manufacturing processes positions domestic brands at the forefront of global standards, driving high-quality development in the industry [33].

Core Insights - Jiangsu Chuangjian Medical's "cross-linked recombinant collagen implant" has been approved by the National Medical Products Administration, marking a significant milestone in the domestic regenerative collagen market [1][12] - The medical aesthetics industry is shifting from simple volume filling to advanced needs for tissue regeneration, with regenerative materials like collagen gaining popularity due to their ability to stimulate the body's own collagen production [1][6] Market Overview - The Chinese medical aesthetics injection market is projected to grow from 21.2 billion RMB in 2023 to 65.3 billion RMB by 2028, with a compound annual growth rate (CAGR) of 25.3% [5] - The regenerative anti-aging injection segment is expected to increase its market share from 3% in 2019 to 31% by 2028, indicating it is the fastest-growing sub-market [5][6] Product Categories - Medical aesthetic injectables can be categorized into hyaluronic acid, botulinum toxin, and regenerative anti-aging materials, with the latter focusing on long-term tissue regeneration rather than just physical filling [3][4] - Regenerative anti-aging injectables are further divided into microsphere regeneration, collagen-based, PDRN, and other categories, emphasizing their role in improving skin quality and addressing aging [4][5] Competitive Landscape - The domestic market for regenerative anti-aging injectables is characterized by a mix of domestic and imported products, with companies like Jinjian Biological, Juzi Biological, and Chuangjian Medical forming a competitive triad [7][12] - As of 2025, there are 15 approved collagen implant products in China, with a notable presence of both animal-derived and recombinant collagen products [10][11] Innovation and Development - Companies are focusing on R&D and regulatory compliance to enhance product quality and market acceptance, with a trend towards stricter approval processes for medical devices [13][14] - Innovations in collagen types and structures are crucial for clinical applications, with companies like Chuangjian Medical achieving significant advancements in the stability and effectiveness of their products [17] Future Trends - The integration of recombinant collagen with microsphere components is expected to create new product forms and market opportunities, positioning domestic companies to play a more significant role in the global medical aesthetics market [19]

Group 1 - The top three companies with the highest short positions are Vanke Enterprises (02202), Dongfang Electric (01072), and COSCO Shipping Holdings (01919), with short ratios of 18.64%, 17.51%, and 16.68% respectively [1][2] - The company with the largest increase in short positions is Dongfang Electric (01072), which saw an increase of 2.20% from the previous short ratio [1][2] - The companies with the largest decrease in short positions include Sanhua Intelligent Control (02050), Tianqi Lithium (09696), and Yuejiang (02432), with decreases of -1.42%, -0.82%, and -0.71% respectively [1][3] Group 2 - The latest short position data shows that Vanke Enterprises has 411 million shares shorted, while Dongfang Electric has 71.45 million shares, and COSCO Shipping Holdings has 480 million shares shorted [2] - The companies with the largest increases in short positions also include JAKS Resources B (01167) and CSPC Pharmaceutical Group (01093), with increases of 0.77% and 0.56% respectively [2] - The companies with the largest decreases in short positions also include Ganfeng Lithium (01772) and Sunac China (01918), with decreases of -0.68% and -0.55% respectively [3][4]